Oral Drug Delivery News

1. Innovative Drug Formulations Make Medicines More Patient-Friendly: Aenova And Galvita Enter Strategic Partnership 7/13/2023

   The Aenova Group is a leading global contract manufacturer and development service provider for the pharmaceutical and healthcare industry. As a full service provider, Aenova develops, produces and packages all common dosage forms, product groups and active ingredient classes from pharmaceuticals to dietary supplements for human and animal health.

2. Acasti Announces WuXi Clinical As CRO To Conduct STRIVE-ON Pivotal Phase 3 Safety Trial For GTX-104 In aSAH Patients 7/10/2023

   Acasti Pharma Inc. (Nasdaq: ACST) ("Acasti" or the "Company"), a late-stage, biopharma company advancing GTX-104, today announced WuXi Clinical Development, Inc. ("WuXi Clinical"), a wholly owned subsidiary of WuXi AppTec, a global Contract Research Organization (CRO), will conduct Acasti's STRIVE-ON Phase 3 safety trial for GTX-104. GTX-104 is Acasti's novel, injectable nimodipine formulation for intravenous infusion (IV) that addresses high, unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH).

3. Ascendia Pharmaceuticals Develops Novel Nanoemulsion IV Formulation For Clopidogrel That Received IND Approval 6/27/2023

   Ascendia Pharmaceuticals CEO Jim Huang, Ph.D. announces Ascendia's patented EmulSol® nanotechnology has been used to develop a novel nanoemulsion IV formulation for clopidogrel that has received Investigational New Drug (IND) approval from the Food & Drug Administration (FDA).

4. Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services Received China Drug Product Manufacturing License, Achieving The Important Milestone In Formulation Capability 4/19/2023

   Crystal Formulation Services, a subsidiary of Crystal Pharmatech, has achieved an exciting new milestone in its formulation capabilities. The company was recently granted the "Drug Manufacturing License" (C Certificate) by the Jiangsu Medical Products Administration, a branch of the Chinese National Medical Products Administration (NMPA).

5. Societal CDMO Announces U.S. FDA Approval For Manufacturing Of Commercial Tablet At Gainesville, Georgia Site 3/20/2023

   Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the United States Food and Drug Administration (FDA) has approved the company as a manufacturer of a commercial tablet product.

6. Shuttle Pharmaceuticals Engages UI Pharmaceuticals For Formulation And Clinical Batch Manufacture Of Ropidoxuridine For Brain Tumor Clinical Trial 3/9/2023

   Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has signed an agreement with the University of Iowa (UI) Pharmaceuticals for formulation development and clinical batch manufacture of drug capsules of Ropidoxuridine.

7. Catalent And Ethicann Sign Development And License Agreement For New Fast-Dissolve Cannabinoid-Based Treatments 1/12/2023

   Catalent, the global leader in enabling the development and supply of better treatments across multiple modalities, and Ethicann Pharmaceuticals Inc., a Canadian/U.S. specialty pharmaceutical company focused on the development of high-value cannabinoid drug therapies, today announced that the companies had executed a development and license agreement to develop Ethicann’s clinical drug pipeline using Catalent’s proprietary Zydis orally disintegrating tablet (ODT) technology.

8. Hovione And GEA Announce A Strategic Collaboration To Advance Continuous Tableting 12/14/2022

   Hovione and GEA today announced a strategic collaboration to advance Continuous Tableting. This partnership stemmed from a successful customer-supplier relationship spanning several years.

9. Lonza Launches New Capsule To Deliver Acid-Sensitive Active Pharmaceutical Ingredients To The Intestine 11/1/2022

   Lonza, a preferred partner to the pharmaceutical, biotech and nutraceutical markets, has launched an innovative new capsule solution for intestinal (enteric) drug delivery.

10. Cingulate Announces Agreement With Societal CDMO And Provides Clinical Update 10/24/2022

    Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it has executed a Master Services Agreement (MSA) with Societal CDMO, Inc. (NASD: SCTL), a bi-coastal contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development.